By NewsDesk  @infectiousdiseasenews Seqirus announced today that it has begun to ship its portfolio of innovative seasonal influenza vaccines across the U.S. in preparation for the 2021/22 influenza...

By NewsDesk  @bactiman63 Seqirus announced this week that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company’s cell-based quadrivalent...

A global leader in influenza prevention, Seqirus presented today absolute efficacy data on the company’s cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT)...

Seqirus announced this week that the US Food and Drug Administration (FDA) has approved FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal...